Invesco Biotechnology & Genome ETF
Invesco Biotechnology & Genome ETF (PBE) Covered Calls
Invesco Biotechnology & Genome ETF trades in the Exchange Traded Fund industry with an IV Rank of 97.22%, high versus the past year. PBE's highest covered call setup is the $100.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 8.00% out of the money with 28 days to expiration, a 8.54% return until expiration, and a 111.36% theoretical annualized return. Across the setups shown, annualized returns run from 44.59% to 111.36% at strikes between $95.00 and $106.00, with 28 to 119 days to expiration, as of Nov 20, 2026.
Read more
Running PBE covered calls helps you generate income from Invesco Biotechnology & Genome ETF shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best PBE covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If PBE stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling PBE covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given PBE covered call is worth writing.
The Invesco Biotechnology & Genome ETF (Fund) is based on the Dynamic Biotech & Genome Intellidex Index (Index). The Fund will normally invest at least 90% of its total assets in the securities that comprise the Index. The Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Index is comprised of securities of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
| 2026-12-18 | 28 | 100.00 | 8.00 | 0.50 | 2.05 | 791.00 | 8.54 | 111.36 | -0.54 | +0.24 | 0 | 1.55 |
| 2026-12-18 | 28 | 99.00 | 6.92 | 0.30 | 2.25 | 671.00 | 7.25 | 94.47 | -0.32 | +0.26 | 0 | 1.95 |
| 2026-12-18 | 28 | 98.00 | 5.84 | 0.55 | 2.50 | 596.00 | 6.44 | 83.91 | -0.59 | +0.30 | 0 | 1.95 |
| 2026-12-18 | 28 | 97.00 | 4.76 | 0.25 | 2.70 | 466.00 | 5.03 | 65.61 | -0.27 | +0.31 | 0 | 2.45 |
| 2027-01-15 | 56 | 101.00 | 9.08 | 0.25 | 3.00 | 866.00 | 9.35 | 60.96 | -0.27 | +0.26 | 0 | 2.75 |
| 2026-12-18 | 28 | 96.00 | 3.68 | 0.60 | 3.00 | 401.00 | 4.33 | 56.46 | -0.65 | +0.36 | 0 | 2.40 |
| 2027-01-15 | 56 | 100.00 | 8.00 | 0.55 | 3.30 | 796.00 | 8.60 | 56.03 | -0.59 | +0.30 | 0 | 2.75 |
| 2026-12-18 | 28 | 95.00 | 2.60 | 0.95 | 3.50 | 336.00 | 3.63 | 47.31 | -1.03 | +0.41 | 9 | 2.55 |
| 2027-01-15 | 56 | 99.00 | 6.92 | 0.05 | 3.50 | 646.00 | 6.98 | 45.48 | -0.05 | +0.30 | 0 | 3.45 |
| 2027-03-19 | 119 | 106.00 | 14.48 | 0.05 | 3.90 | 1346.00 | 14.54 | 44.59 | -0.05 | +0.25 | 0 | 3.85 |
As of Nov 20, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryExchange Traded Fund
- SectorFinancial
- IV Rank97.22% High
- Market cap (M$)—
- 52 weeks high-11.56%
- 52 weeks low22.64%
- Analyst recommendation—
- Target price—
- Dividend—
- Payout ratio—
- Earnings date—
- P/E—
- Future P/E—
- EPS (ttm)—
- EPS growth next 5 years—
As of Nov 20, 2026